SHA: 603222

Company Drug

Jemincare JMX-2005 PAD Injection Secures NMPA Clinical Trial Approval

Fineline Cube Dec 23, 2025

Jiangxi Jemincare Group (SHA: 603222) announced that its Class 2.2 and Class 2.4 new drug application for...

Company Drug

Jiangxi Jemincare Group Secures Clinical Trial Approvals for Six Drugs in China and the US

Fineline Cube Dec 26, 2023

China-based Jiangxi Jemincare Group (SHA: 603222) has announced receiving clinical trial approvals for six of...

Company Drug

Henlius Triple Combo Gets NMPA Nod for Advanced Solid Tumor Trials

Company Drug

Hengrui’s HRS-5346 Lp(a) Inhibitor Gets China Breakthrough Therapy Designation in $1.97B Merck Deal

Company Deals Medical Device

IVD Medical Launches Nipah Virus Detection Kit with AI Early Warning Platform

Company Drug

Betta Pharmaceuticals’ BPI-572270 RAS Inhibitor Gets NMPA Nod for Solid Tumor Trials